{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "Favipiravir",
      "Immunoglobulin G",
      "Inmunoglobulina G",
      "Ivermectin",
      "Ivermectina",
      "Neumon\u00eda",
      "Nitazoxanida",
      "Nitazoxanide",
      "Pneumonia",
      "SARS-CoV-2",
      "Tocilizumab"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33877121",
  "DateCompleted": {
    "Year": "2021",
    "Month": "04",
    "Day": "26"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "04",
    "Day": "26"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.24875/GMM.M21000461"
    ],
    "Journal": {
      "ISSN": "0016-3813",
      "JournalIssue": {
        "Volume": "156",
        "Issue": "6",
        "PubDate": {
          "Year": "2020"
        }
      },
      "Title": "Gaceta medica de Mexico",
      "ISOAbbreviation": "Gac Med Mex"
    },
    "ArticleTitle": "Guidelines for clinical management of SARS-CoV-2 infection.",
    "Pagination": {
      "StartPage": "576",
      "EndPage": "583",
      "MedlinePgn": "576-583"
    },
    "Abstract": {
      "AbstractText": [
        "In SARS-CoV-2 infection (COVID-19), the most common manifestations involve the upper airways; in complicated cases, bilateral interstitial pneumonia, severe acute respiratory failure and multiple organ failure occur, which require hospital treatment and ventilatory support with nasal cannula or mask and high flow oxygen, or orotracheal intubation and mechanical ventilation. There are no specific antivirals, and thus management is symptomatic, as well as with antiplatelet drugs (acetylsalicylic acid, dipyridamole), low molecular weight heparin when there is hypercoagulability (increased D-dimer), dexamethasone when inflammation indicators are elevated; experimentally, under informed consent, antibiotics are used according to microbiological results, as well as interferon beta 1b, favipiravir, tocilizumab, ivermectin and immunoglobulin G. When gastroenteritis occurs, nitazoxanide can be indicated. En infecci\u00f3n por SARS-CoV-2 (COVID-19), las manifestaciones m\u00e1s comunes son las de v\u00edas a\u00e9reas superiores; en casos complicados se presenta neumon\u00eda intersticial bilateral, insuficiencia respiratoria aguda grave y falla org\u00e1nica m\u00faltiple que ameritan tratamiento hospitalario y soporte ventilatorio por puntas nasales o mascarilla, as\u00ed como ox\u00edgeno con flujo a presi\u00f3n alta o intubaci\u00f3n orotraqueal y ventilaci\u00f3n mec\u00e1nica. No hay antivirales espec\u00edficos por lo que el manejo es sintom\u00e1tico, as\u00ed como con antiplaquetarios (\u00e1cido acetilsalic\u00edlico, dipiridamol), heparina de bajo peso molecular ante hipercoagulabilidad (d\u00edmero D aumentado), dexametasona ante indicadores altos de inflamaci\u00f3n. Previo consentimiento informado, experimentalmente se emplean antibi\u00f3ticos seg\u00fan los resultados microbiol\u00f3gicos, interfer\u00f3n beta 1b, favipiravir, tocilizumab, ivermectina e inmunoglobulina G. Cuando se presenta gastroenteritis se puede indicar nitazoxanida."
      ],
      "CopyrightInformation": "Copyright: \u00a9 2020 Permanyer."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Pharmacology Department, Faculty of Medicine, Universidad Nacional Aut\u00f3noma de M\u00e9xico, Mexico City, Mexico."
          }
        ],
        "LastName": "Garc\u00eda-\u00c1lvarez",
        "ForeName": "Jos\u00e9 L",
        "Initials": "JL"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Pharmacology Department, Faculty of Medicine, Universidad Nacional Aut\u00f3noma de M\u00e9xico, Mexico City, Mexico."
          }
        ],
        "LastName": "Garc\u00eda-Vigil",
        "ForeName": "Jos\u00e9 L",
        "Initials": "JL"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ],
    "VernacularTitle": "Gu\u00eda de manejo cl\u00ednico del paciente con infecci\u00f3n por SARS-CoV-2."
  },
  "MedlineJournalInfo": {
    "Country": "Mexico",
    "MedlineTA": "Gac Med Mex",
    "NlmUniqueID": "0010333",
    "ISSNLinking": "0016-3813"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "complications",
        "physiopathology",
        "therapy"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Intubation, Intratracheal"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Practice Guidelines as Topic"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Respiration, Artificial"
    },
    {
      "QualifierName": [
        "isolation & purification"
      ],
      "DescriptorName": "SARS-CoV-2"
    }
  ]
}